
30
Fármacos utilizados en el tratamiento de la enfermedad de Alzheimer y otras demencias
22. Janicak PG, Marder SR, Pavuluri MN. Principles and Practice of Psychopharmacotherapy. 5ta edición. Lip-
pincott Williams & Wilkins; 2011.
23. Knapp MJ, Knopman DS, Solomon PR, Pendlebury WW, Davis CS, Gracon SI. A 30-week randomized con-
trolled trial of high-dose tacrine in patients with Alzheimer´s disease. JAMA. 1994; 271 (1): 985-991.
24. Labbate LA, Fava M, Rosenbaum JF, Arana GW. Handbook of Psychiatric Drug Therapy. 6ta edición. Phila-
delphia: Lippincott Williams & Wilkins; 2010.
25. Lockhart IA, Mitchell SA & Kelly S: Safety and tolerability of donepezil, rivastigmine and galantamine
for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dement Geriatr Cogn
Disord. 2009; 28:389-403.
26. Loy C & Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane
Database Syst Rev. 2006; CD001747.
27. Massoud F & Gauthier S. Update on the Pharmacological Treatment of Alzheimer´s Disease. Current
Neuropharmacology. 2010; 8: 69-80.
28. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of
dementia with Lewy bodies: Third report of the DLB consortium. Neurology. 2005; 65 (12): 1863-1872.
29. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of demen-
tia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Associa-
tion Workgroups on diagnostic guidelines for Alzheimer´s disease. Alzheimers Dement. 2011; 7 (3): 263-269.
30. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database of Systematic
Reviews. 2006; 2: CD003154. DOI: 10.1002/14651858. CD003154.pub5
31. Mesulam M, Geula C. Butyrilcholinesterase reactivity dierentiates the amyloid plaques of aging from
those of dementia. Ann Neurol. 1994; 36: 722-727.
32. Patel L, Grossberg GT. Combination therapy for Alzheimer's disease. Drugs Aging. 2011 Jul 1;28(7):539-46.
33. Procyshyn RM, Bezchlibnyk-Butler KZ, Jeries JJ. Clinical handbook of Psychotropic Drugs. 21ta edición
revisada. Hogrefe & Huber Publishers; 2015.
34. Richly P, Manes F, Bustin J. Depression in Alzheimer´s disease. En: Kanner AM, editor. Depression in Neuro-
logic Disorders. Diagnosis and Management. EE. UU.: Willey-Blackwell; 2012.
35. Robert P. Understanding and Managing Behavioural Symptoms in Alzheimer´s Disease and Related De-
mentias: Focus on Rivastigmine. Curr Med Res Opinion. 2002; 18 (3): 156-171.
36. Rogers SL, Friedho LT. The ecacy and safety of donepezil in patients with Alzheimer´s disease: result
of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. De-
mentia. 1996; 7 (6): 293-303.
37. Rogers SL, Farlow MR, et al. A 24-week, double-bind, placebo-controlled trial of Aricept in patients with
Alzheimer´s disease. Neurology. 1998; 50: 136-145.
38. Schatzberg AF, DeBattista Ch. Manual of Clinical Psychopharmacology. 8a edición. American Psychiatric
Publishing; 2015.
39. Stahl SM. Stahl’s essential psychopharmacology: the prescriber’s guide. 4ta edición. Nueva York: Cambridge
University Press; 2011.
40. Tariot PN, Solomon PR, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD.
Neurology. 2000; 54: 2269-2276.
41. Tisher A & Arash S. “A comprehensive update on treatment of dementia”. Seminars in neurology. Vol. 39.
No. 02. Thieme Medical Publishers; 2019.
42. Vaz, Miguel, et al. "Role of Aducanumab in the Treatment of Alzheimer’s Disease: Challenges and Oppor-
tunities". Clinical Interventions in Aging 17 (2022): 797.
43. Watkins PB, Zimmerman HJ, Knapp MJ, Gracon SI, Lewis KW. Hepatotoxic eects of tacrine administra-
tion in patients with Alzheimer´s disease. JAMA. 1994; 271 (13): 992-998.